摘要:
A hetrazepine of the formula given below and a pharmaceutical composition comprising a therapeutically effective amount of the hetrazepine and a pharmaceutically acceptable inert carrier are disclosed and are useful in treating disease in a warm-blooded animal induced by endogenously formed PAF; ##STR1## wherein the substituents are defined herein.
摘要:
The present invention relates to thienodiazepines of formula Ib: ##STR1## wherein U, V, R.sub.5, R.sub.6 and R.sub.7 are as defined herein. This invention also relates to processes for preparing these thienodiazepines and their use in pharmaceutical compositions with PAF-antagonistic activity.
摘要:
The invention relates to new diazephines of the formula ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined herein, processes for preparing them and their use as pharmaceutical compositions useful for treating PAF-induced disease.
摘要:
Xanthines of the formula I ##STR1## wherein R.sub.1 is a C.sub.1 -C.sub.4 alkyl group:R.sub.2 is a C.sub.1 -C.sub.4 alkyl group;R.sub.3 tetrahydropyran-4-yl or 1,3-dithiolan or;R.sub.3 represents one of the groups of formula ##STR2## and pharmaceutically acceptable acid addition salts thereof. These are adenosine antagonists, capable of acting as cholinomimetics, useful for the treatment of CNS disorders such as senile dementia and Alzheimer's disease.
摘要:
The invention relates to new 1,4-diazepines of the general formula ##STR1## in which R.sub.1, R.sub.2 R.sub.3, X and A have the meaning indicated in the specification.The new compounds are intended for use for the treatment of pathological states and diseases in which PAF (platelet activating factor) is involved.
摘要:
The invention relates to new tetrahydropyridine derivatives, processes for preparing them and their use as pharmaceutical compositions with cholinomimetic properties.
摘要:
The invention relates to new thieno-1,4-diazepines of general formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.degree., R', Z, X, Y and n have the meanings given in the specification.The new compounds are intended to be used in the treatment of pathological conditions and diseases in which PAF (platelet activating factor) is implicated.